| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Ludwig Institute for Cancer Research, B-1200 Brussels [E. S. S., B. L., J. V. S., P. C., T. B., P. v. d. B.]; Experimental Medicine Unit, Catholic University of Louvain, B-1200 Brussels [C. L. C.]; and Laboratory of Physiology, Medical School, Free University of Brussels, B-1090 Brussels [J. C., C. H., K. T.], Belgium
Antigens encoded by MAGE-A3 and recognized by T cells are
interesting targets for tumor immunotherapy because they are strictly
tumor specific and shared by many tumors of various histological types.
A number of MAGE-A3 antigenic peptides presented by HLA class I
molecules have been used in clinical trials, and regressions of
melanoma metastasis have been observed. We report here the
identification of a MAGE-A3 epitope, TQHFVQENYLEY, presented to
CD4+ T lymphocytes by HLA-DP4 molecules, which are
expressed in 
76% of Caucasians. This new epitope may be useful both
for therapeutic vaccination and for the evaluation of the immune
response in cancer patients. Interestingly, the CD4+ T
cells lysed HLA-DP4 tumor cells expressing MAGE-A3,
indicating that this epitope, in contrast to other class-II MAGE-A3
epitopes, is presented at the surface of tumor cells. The study of this
disparity in the presentation of two epitopes from the same protein may
lead to a better understanding of the endogenous class II presentation
pathway.
This article has been cited by other articles:
|
|
 |
|
  R. Crocchiolo, E. Zino, L. Vago, R. Oneto, B. Bruno, S. Pollichieni, N. Sacchi, M. P. Sormani, J. Marcon, T. Lamparelli, et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation Blood, August 13, 2009; 114(7): 1437 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bonehill, A. M.T. Van Nuffel, J. Corthals, S. Tuyaerts, C. Heirman, V. Francois, D. Colau, P. van der Bruggen, B. Neyns, and K. Thielemans Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients Clin. Cancer Res., May 15, 2009; 15(10): 3366 - 3375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fontana, M. Bregni, A. Cipponi, L. Raccosta, C. Rainelli, D. Maggioni, F. Lunghi, F. Ciceri, S. Mukenge, C. Doglioni, et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients Blood, February 19, 2009; 113(8): 1651 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. C. Goodyear, G. Pratt, A. McLarnon, M. Cook, K. Piper, and P. Moss Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma Blood, October 15, 2008; 112(8): 3362 - 3372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marturano, R. Longhi, V. Russo, and M. P. Protti Endosomal Proteases Influence the Repertoire of MAGE-A3 Epitopes Recognized In vivo by CD4+ T Cells Cancer Res., March 1, 2008; 68(5): 1555 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Carrasco, A. Van Pel, B. Neyns, B. Lethe, F. Brasseur, N. Renkvist, P. van der Bruggen, N. van Baren, R. Paulus, K. Thielemans, et al. Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells J. Immunol., March 1, 2008; 180(5): 3585 - 3593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Shaw, T. A. Gooley, M. Malkki, J. A. Madrigal, A. B. Begovich, M. M. Horowitz, A. Gratwohl, O. Ringden, S. G. E. Marsh, and E. W. Petersdorf The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation Blood, December 15, 2007; 110(13): 4560 - 4566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Erfurt, Z. Sun, I. Haendle, B. Schuler-Thurner, C. Heirman, K. Thielemans, P. van der Bruggen, G. Schuler, and E. S. Schultz Tumor-Reactive CD4+ T Cell Responses to the Melanoma-Associated Chondroitin Sulphate Proteoglycan in Melanoma Patients and Healthy Individuals in the Absence of Autoimmunity J. Immunol., June 15, 2007; 178(12): 7703 - 7709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Janjic, P. Andrade, X.-F. Wang, J. Fourcade, C. Almunia, P. Kudela, A. Brufsky, S. Jacobs, D. Friedland, R. Stoller, et al. Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers J. Immunol., August 15, 2006; 177(4): 2717 - 2727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. McWilliams, S. M. McGurran, S. W. Dow, J. E. Slansky, and R. M. Kedl A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model J. Immunol., July 1, 2006; 177(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Cohen, S. Pouvelle-Moratille, X.-F. Wang, S. Farci, G. Munier, D. Charron, A. Menez, M. Busson, and B. Maillere Scanning the HIV Genome for CD4+ T Cell Epitopes Restricted to HLA-DP4, the Most Prevalent HLA Class II Molecule J. Immunol., May 1, 2006; 176(9): 5401 - 5408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Shaw, S. G.E. Marsh, N. P. Mayor, N. H. Russell, and J. A. Madrigal HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants Blood, February 1, 2006; 107(3): 1220 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Neumann, C. Wagner, K.-D. Preuss, B. Kubuschok, C. Schormann, S. Stevanovic, and M. Pfreundschuh Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells Blood, November 1, 2005; 106(9): 3105 - 3113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dieckmann, E. S. Schultz, B. Ring, P. Chames, G. Held, H. R. Hoogenboom, and G. Schuler Optimizing the exogenous antigen loading of monocyte-derived dendritic cells Int. Immunol., May 1, 2005; 17(5): 621 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ayyoub, A. Merlo, C. S. Hesdorffer, D. Rimoldi, D. Speiser, J.-C. Cerottini, Y.-T. Chen, L. J. Old, S. Stevanovic, and D. Valmori CD4+ T Cell Responses to SSX-4 in Melanoma Patients J. Immunol., April 15, 2005; 174(8): 5092 - 5099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, Z. Sun, H. Nicolay, R. G. Meyer, N. Renkvist, V. Stroobant, J. Corthals, J. Carrasco, A. M. M. Eggermont, M. Marchand, et al. Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein J. Immunol., February 15, 2005; 174(4): 2404 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bonehill, C. Heirman, S. Tuyaerts, A. Michiels, K. Breckpot, F. Brasseur, Y. Zhang, P. van der Bruggen, and K. Thielemans Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules J. Immunol., June 1, 2004; 172(11): 6649 - 6657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ayyoub, C. S. Hesdorffer, G. Metthez, S. Stevanovic, G. Ritter, Y.-T. Chen, L. J. Old, D. Speiser, J.-C. Cerottini, and D. Valmori Identification of an SSX-2 Epitope Presented by Dendritic Cells to Circulating Autologous CD4+ T Cells J. Immunol., June 1, 2004; 172(11): 7206 - 7211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Atanackovic, N. K. Altorki, E. Stockert, B. Williamson, A. A. Jungbluth, E. Ritter, D. Santiago, C. A. Ferrara, M. Matsuo, A. Selvakumar, et al. Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients J. Immunol., March 1, 2004; 172(5): 3289 - 3296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Breckpot, C. Heirman, C. De Greef, P. van der Bruggen, and K. Thielemans Identification of New Antigenic Peptide Presented by HLA-Cw7 and Encoded by Several MAGE Genes Using Dendritic Cells Transduced with Lentiviruses J. Immunol., February 15, 2004; 172(4): 2232 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zino, G. Frumento, S. Marktel, M. P. Sormani, F. Ficara, S. D. Terlizzi, A. M. Parodi, R. Sergeant, M. Martinetti, A. Bontadini, et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation Blood, February 15, 2004; 103(4): 1417 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Schultz, B. Schuler-Thurner, V. Stroobant, L. Jenne, T. G. Berger, K. Thielemanns, P. van der Bruggen, and G. Schuler Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy J. Immunol., January 15, 2004; 172(2): 1304 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. de Rijke, H. Fredrix, A. Zoetbrood, F. Scherpen, H. Witteveen, T. de Witte, E. van de Wiel-van Kemenade, and H. Dolstra Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy Blood, October 15, 2003; 102(8): 2885 - 2891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mandic, C. Almunia, S. Vicel, D. Gillet, B. Janjic, K. Coval, B. Maillere, J. M. Kirkwood, and H. M. Zarour The Alternative Open Reading Frame of LAGE-1 Gives Rise to Multiple Promiscuous HLA-DR-restricted Epitopes Recognized by T-helper 1-type Tumor-reactive CD4+ T Cells Cancer Res., October 1, 2003; 63(19): 6506 - 6515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bonehill, C. Heirman, S. Tuyaerts, A. Michiels, Y. Zhang, P. van der Bruggen, and K. Thielemans Efficient Presentation of Known HLA Class II-restricted MAGE-A3 Epitopes by Dendritic Cells Electroporated with Messenger RNA Encoding an Invariant Chain with Genetic Exchange of Class II-associated Invariant Chain Peptide Cancer Res., September 1, 2003; 63(17): 5587 - 5594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, P. Chaux, V. Stroobant, A. M. M. Eggermont, J. Corthals, B. Maillere, K. Thielemans, M. Marchand, T. Boon, and P. van der Bruggen A MAGE-3 Peptide Presented by HLA-DR1 to CD4+ T Cells That Were Isolated from a Melanoma Patient Vaccinated with a MAGE-3 Protein J. Immunol., July 1, 2003; 171(1): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Slager, M. Borghi, C. E. van der Minne, C. A. Aarnoudse, M. J. E. Havenga, P. I. Schrier, S. Osanto, and M. Griffioen CD4+ Th2 Cell Recognition of HLA-DR-Restricted Epitopes Derived from CAMEL: A Tumor Antigen Translated in an Alternative Open Reading Frame J. Immunol., February 1, 2003; 170(3): 1490 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Consogno, S. Manici, V. Facchinetti, A. Bachi, J. Hammer, B. M. Conti-Fine, C. Rugarli, C. Traversari, and M. P. Protti Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 Blood, February 1, 2003; 101(3): 1038 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Castelli, C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Segard, J.-G. Guillet, A. Menez, B. Georges, et al. HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity J. Immunol., December 15, 2002; 169(12): 6928 - 6934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dorothee, I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin, S. Chouaib, and F. Mami-Chouaib Tumor-Infiltrating CD4+ T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-{alpha} on APO2L/TRAIL Expression and -Mediated Cytotoxicity J. Immunol., July 15, 2002; 169(2): 809 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hural, R. S. Friedman, A. McNabb, S. S. Steen, R. A. Henderson, and M. Kalos Identification of Naturally Processed CD4 T Cell Epitopes from the Prostate-Specific Antigen Kallikrein 4 Using Peptide-Based In Vitro Stimulation J. Immunol., July 1, 2002; 169(1): 557 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schuler-Thurner, E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, et al. Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells J. Exp. Med., May 20, 2002; 195(10): 1279 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Zarour, B. Maillere, V. Brusic, K. Coval, E. Williams, S. Pouvelle-Moratille, F. Castelli, S. Land, J. Bennouna, T. Logan, et al. NY-ESO-1 119-143 Is a Promiscuous Major Histocompatibility Complex Class II T-Helper Epitope Recognized by Th1- and Th2-Type Tumor-reactive CD4+ T Cells Cancer Res., January 1, 2002; 62(1): 213 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zammatteo, L. Lockman, F. Brasseur, E. De Plaen, C. Lurquin, P.-E. Lobert, S. Hamels, T. Boon, and J. Remacle DNA Microarray to Monitor the Expression of MAGE-A Genes Clin. Chem., January 1, 2002; 48(1): 25 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, Y. Song, D. S. B. Hoon, E. Appella, and E. Celis Tumor-reactive T Helper Lymphocytes Recognize a Promiscuous MAGE-A3 Epitope Presented by Various Major Histocompatibility Complex Class II Alleles Cancer Res., June 1, 2001; 61(12): 4773 - 4778. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
